How this Dutch startup is helping paralyzed patients move again
In 2012, when a tree fell on her family's car, Jessie Owen's life transformed. Both of her parents died, and the then-27-year-old Owen was paralyzed. 'I lost everything overnight: my independence, career, home,' she says. 'And it's hard to rank them, but losing my autonomy to control my own body was up there.'
Her spinal cord injury left her with some limited movement, but fine motor skills were especially challenging. Then, a few years ago, she took part in a clinical study of new technology: a device called ARC-EX, which temporarily attaches electrodes to the skin to stimulate sensory nerves in the spine. After a few weeks of therapy, Owen could tie her shoes, open a jar of peanut butter, and drink from a glass without a straw. 'There's a quiet dignity in needing less help,' she says.
Results of the study appeared in Nature Medicine last year, showing improvements in hand strength or function among 90% of participants. Owen also saw her blood pressure stabilize, and she no longer had neuropathic pain. In the past, after an injury, patients with quadriplegia typically got three months of rehab and were then told nothing more could be done. The study showed it was possible to help people with 34-year-old injuries.
The device, which spun out of research at UCLA, became the first of its kind to get FDA clearance last December. Headquartered in the Netherlands, the medical tech company Onward is bringing ARC-EX to market, with plans to use it at 10 clinics before it becomes widely available later this year. The company is also running studies on an implantable version and a third platform with a brain-computer interface that can help people move again using their thoughts.
Explore the full list of Fast Company's World Changing Ideas, 100 inspiring projects that are making the world more accessible, equitable, and sustainable for everyone.
The final deadline for Fast Company's Next Big Things in Tech Awards is Friday, June 20, at 11:59 p.m. PT. Apply today.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide. Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages. Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio. America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. "We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines." Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients." "As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter. "Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said. Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans. Contacts : Hikma Pharmaceuticals PLC Investors Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Media Steven Weiss US Communications +1 732 788 8279 About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: View original content to download multimedia: SOURCE Hikma Pharmaceuticals USA Inc.
Yahoo
9 hours ago
- Yahoo
Soybeans On the Higher Side of Unchanged to Start Friday
The soybean market is trying to end the week on a higher note, with front months fractionally higher and November up 2 cents. Soybeans posted Thursday losses of 1 to 3 cents at the close, as multi-year lows in Meal are adding to the pressure. The cmdtyView national average Cash Bean price was up 1/4 cents at $9.79 1/2. Soymeal futures were another $4.70 to $5.40/ton lower, hitting the lowest prices on the front month chart since 2016. Soy Oil were up 56 to 69 points on the day. Export Sales data from Thursday morning tallied 402,931 MT of 2024/25 soybeans sold in the week ending on June 19. That was back down from the week prior, but still up 42.4% from the same week in 2024. The Netherlands was the top buyer of 63,400 MT, with Mexico in from 60,600 MT and 60,000 MT sold to Egypt. New crop sales were tallied at 156,153 MT, the third highest in the MY. Mexico was the buyer of 57,200 MT, with 55,000 MT sold to unknown destinations. Coffee Prices Move Higher as the Dollar Falls Coffee Prices Rally as the Dollar Falls Cocoa Prices Jump as Ghana Cuts its Cocoa Production Forecast Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Sales for soybean meal were just 93,945 MT for 2024/25 and 166,129 MT for 2025/26, totaling 260,074 MT and on the low side of the expected 100,000 and 650,000 MT. Soybean oil sales were 4,023 MT, on the low side of the estimate of net reductions of 10,000 MT to net sales of 34,000 MT. Datagro estimates the Brazilian soybean crop at 173.5 MMT, which was a 1.5 MMT increase from the prior numbers. Jul 25 Soybeans closed at $10.22 3/4, down 2 1/2 cents, currently up 1/2 cent Nearby Cash was $9.79 1/2, up 1/4 cent, Aug 25 Soybeans closed at $10.27 3/4, down 1 3/4 cents, currently up 3/4 cent Nov 25 Soybeans closed at $10.16 1/2, down 2 cents, currently up 2 cents New Crop Cash was $9.65 1/1, down 1/4 cent, On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
